Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Lyell Immunopharma Inc (NASDAQ: LYEL) closed the day trading at $30.78 down -2.56% from the previous closing price of $31.59. In other words, the price has decreased by -$2.56 from its previous closing price. On the day, 0.19 million shares were traded. LYEL stock price reached its highest trading level at $32.275 during the session, while it also had its lowest trading level at $30.02.
Ratios:
For a better understanding of LYEL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.30 and its Current Ratio is at 10.30. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
On October 30, 2024, BofA Securities Downgraded its rating to Underperform which previously was Buy and also lowered its target price recommendation from $6 to $1.
H.C. Wainwright Downgraded its Buy to Neutral on June 27, 2024, whereas the target price for the stock was revised from $6 to $1.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 10 ’25 when Seely Lynn sold 412 shares for $16.11 per share. The transaction valued at 6,637 led to the insider holds 67,159 shares of the business.
Bulis Veronica Sanchez sold 239 shares of LYEL for $3,848 on Nov 10 ’25. The VP, Corporate Controller now owns 9,213 shares after completing the transaction at $16.10 per share. On Nov 10 ’25, another insider, Lee Gary K., who serves as the Chief Scientific Officer of the company, sold 138 shares for $16.16 each. As a result, the insider received 2,230 and left with 15,366 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 653888896 and an Enterprise Value of 377757728. For the stock, the TTM Price-to-Sale (P/S) ratio is 16347.31 while its Price-to-Book (P/B) ratio in mrq is 1.80. Its current Enterprise Value per Revenue stands at 9213.603 whereas that against EBITDA is -2.049.
Stock Price History:
The Beta on a monthly basis for LYEL is -0.12, which has changed by 1.4488373 over the last 52 weeks, in comparison to a change of 0.17511821 over the same period for the S&P500. Over the past 52 weeks, LYEL has reached a high of $45.00, while it has fallen to a 52-week low of $7.65. The 50-Day Moving Average of the stock is 29.27%, while the 200-Day Moving Average is calculated to be 116.90%.
Shares Statistics:
Over the past 3-months, LYEL traded about 58.96K shares per day on average, while over the past 10 days, LYEL traded about 150600 shares per day. A total of 19.29M shares are outstanding, with a floating share count of 6.94M. Insiders hold about 67.31% of the company’s shares, while institutions hold 13.31% stake in the company. Shares short for LYEL as of 1765756800 were 164482 with a Short Ratio of 2.79, compared to 1763078400 on 163125. Therefore, it implies a Short% of Shares Outstanding of 164482 and a Short% of Float of 0.9299999999999999.
Earnings Estimates
Lyell Immunopharma Inc (LYEL) is presently subject to a detailed evaluation by 4.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$2.14, with high estimates of -$2.12 and low estimates of -$2.16. Analysts are recommending an EPS of between -$10.04 and -$11.92 for the fiscal current year, implying an average EPS of -$10.61. EPS for the following year is -$9.05, with 4.0 analysts recommending between -$7.35 and -$9.78.
